Saturday, January 14, 2023 1:17:37 PM
The bulk of the trial data, 500 out of 710 people is still locked up and no one has seen or analyzed that data, in total.
Thus the FDA has very limited data. So how are the delays the FDA's fault?
Limited funding small firms, must crawl, before the walk, and walk before they can run, and use every $ they raise wizely.
The big Biotechs can burn 10s of millions of dollars and never notice it.
Thus the FDA has very limited data. So how are the delays the FDA's fault?
Limited funding small firms, must crawl, before the walk, and walk before they can run, and use every $ they raise wizely.
The big Biotechs can burn 10s of millions of dollars and never notice it.
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
